Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of nirsevimab for prevention of RSV lower respiratory tract disease in healthy preterm and term infants in China
CTR20212144Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Nirsevimab with Placebo (2 arms). Started Nov 2021; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20212144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212144.